Across TCGA pan-cancer cohorts, ANKRD30BP2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANKRD30BP2 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ANKRD30BP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD30BP2 expression acts as an unfavorable survival marker.

COAD, UCEC, and LIHC are the cancer types where ANKRD30BP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.111	0.871	<.001	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.167	0.688	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ANKRD30BP2 tumor-vs-normal RNA expression · all ANKRD30BP2 data types